Within a selection of therapies showing efficacy over a placebo, lenalidomide-carfilzomib was a standout against the rest of the group.
Novel agents and combination treatment regimens have advanced the treatment of multiple myeloma (MM) in recent decades, but identifying the best maintenance treatment regimen has proven challenging. A recent review and analysis published in the journal Hematology suggests that lenalidomide-carfilzomib is the most effective option, although further studies are necessary to confirm.
“Despite advances in novel agents, the relapse and progression of MM were still inevitable after induction and consolidation treatment,” the authors wrote. “Therefore, to conquer this dilemma, literally to prolong the long-term survival of MM patients, maintenance therapies presumably enhancing the response of initial treatment have been proposed and widely investigated.”
Several maintenance therapy strategies have been studied in recent decades, but many came with significant toxicity that outweighed their efficacy. The immunomodulatory drug lenalidomide was established as an effective option and became the MM maintenance treatment standard in 2005. More recently, the proteasome inhibitors bortezomib, carfilzomib, and ixazomib, as well as the monoclonal antibodies daratumumab and elotuzumab have expanded the therapy armamentarium.
Despite a growing roster of treatment options, a lack of direct comparisons between the various drug options makes it difficult for clinicians to choose the best treatment strategy. The review authors aimed to provide clarity on the most appropriate treatment options by also conducting a network meta-analysis to form indirect comparisons between regimens.
The analysis included a total of 19 trials encompassing 8337 patients with newly diagnosed MM and 11 maintenance therapy options. The main end point was overall survival (OS), and odds ratios (ORs) were generated for dichotomous variants. Progression-free survival (PFS) was also assessed.
Lenalidomide and daratumumab were each significantly more effective than a placebo when it came to OS, with OR ranges of 1.61 to 1.9 and 1.83 to 2.41, respectively. Where PFS is concerned, combination lenalidomide-carfilzomib, combination lenalidomide-prednisone, combination bortezomib-thalidomide, daratumumab, lenalidomide, ixazomib, and thalidomide all were effective vs a placebo.
Within the group of therapies showing efficacy over a placebo, lenalidomide-carfilzomib was a standout against the rest of the group, including lenalidomide, daratumumab, and ixazomib. Overall, considering both OS and PFS, lenalidomide plus carfilzomib was the authors’ recommended maintenance therapy option. However, they note that further head-to-head studies could help confirm its superiority over other therapies. This regimen also carries a risk of adverse events as well as a financial burden that clinicians should consider.
Limitations of the study included potential missed literature, the study’s analysis of PFS and OS alone, and the limited number of studies overall—particularly for newer regimens.
“In conclusion, post-autologous stem cell transplantation maintenance therapy with lenalidomide continued is the current standard of care based on the available clinical trial data, the most likely next step will be to incorporate carfilzomib into the maintenance setting,” the authors wrote.
“Physicians also need to be vigilant about the risk of adverse event and cost-economic in MM patients treated with lenalidomide-carfilzomib. More head-to-head clinical trials are needed to confirm our findings.”
Reference
Zhi Y, Bao S, Mao J, et al. Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis. Hematology. Published online September 20, 2022. doi:10.1080/16078454.2022.2121900
Study Urges Personalized Care to Boost Quality of Life in Patients With MM
April 11th 2024Treatment and management of multiple myeloma (MM) is continuously evolving, and in this analysis, investigators discuss ever-present issues and potential solutions to optimize care for this patient population.
Read More
FDA Approves Cilta-Cel for Earlier Treatment of RRMM
April 6th 2024Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More
Fracture Risk Lowest for Alendronate, Pamidronate Use During MM Treatment
March 21st 2024In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from facilitating jaw degradation and reducing vertebral fracture risk among patients being treated for multiple myeloma.
Read More